Clinical Trial Update: Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating hippocampus-sparing radiotherapy in combination with osimertinib for symptomatic brain metastases in EGFR-mutated, treatm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Naive Advanced Non-small Cell Lung Cancer With EGFR-sensitive Mutations (EGFR Exon 19 Deletion and Exon 21 L858R Mutation) and Symptomatic Brain Metastases | Phase 2 | Status: RECRUITING